Navigation Links
Scripps Research scientist wins $1.9 million grant to study malaria
Date:6/9/2011

A scientist from The Scripps Research Institute has won a four-year, $1.9 million grant from the National Institutes of Health to better understand the parasite that causes malaria, laying the groundwork to develop better drugs to combat the widespread and deadly disease.

"Many antimalarial drugs alleviate symptoms, but do not necessarily result in a complete cure because some malaria parasites are able to persist asymptomatically in the liver for months or years," said Scripps Research Professor Elizabeth Winzeler, who is principal investigator for the new grant. "We hope to find new targets that are critical to the liver stages as well as the blood stages with the long-term aim of designing better drugs."

A Complicated Lifecycle

Malaria is a nasty and often fatal disease, affecting about 250 million people every year in Africa, Asia, and the Americas, according to the World Health Organization (WHO). Each year, more than 1 million people die of malaria, mostly children under the age of five. While significant strides had been made in curtailing the disease, for the last two decades malaria, has again been on the rise due to the emergence of drug-resistant parasites.

The parasite Plasmodium, which causes malaria, has a complicated lifecycle in two hostsmosquitoes and humans (or other vertebrate). When a malaria-infected mosquito feeds on a person, the parasite enters the human body. Within 30 minutes, the parasite has infected liver cells, where it remains anywhere from eight days to several months without causing noticeable symptoms.

When this period is over, however, the parasite (now in a different form) leaves the liver and enters red blood cells, where it grows and multiplies. When the infected red blood cells eventually burst, the parasite and Plasmodium toxins are released into the bloodstream, and the person feels sick. Symptoms include fever, chills, headache, and other flulike symptoms; in severe cases, patients can experience convulsions, coma, and liver and kidney failure, which can be fatal.

If a mosquito bites the infected person at this point, the parasite will enter the mosquito, where it will continue the cycle by maturing into a form that can infect the next human host.

Untapped Opportunities

Because most antimalarial drugs have targeted the malaria parasite in its blood stages, Winzeler believes there are untapped opportunities to combat the disease in the liver stages of the parasite's lifecycle. That's where the new grant comes in.

The new grant from the NIH National Institute of Allergy and Infectious Diseases will fund research in the Winzeler lab investigating pathways essential to parasite development in both blood and liver stages. Specifically, the lab will look at the development of parasite's resistance to antimalarial compounds in culture. The team will then endeavor to identify and characterize the genetic mutations enabling the drug resistance, providing new information on potential drug targets.

"The work may lead to a better understanding of how to treat tissue-stage malaria, provide new antibiotic resistance genes, and provide information about how eukaryotic pathogens become resistant to drugs," Winzeler said.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research scientists find way to block stress-related cell death
2. Scripps Research scientists find key mechanism in transition to alcohol dependence
3. Scripps Research scientists create new genetic model of premature aging diseases
4. Scripps Research scientists identify mechanism of long-term memory
5. Scripps Research scientists uncover new DNA role in modifying gene function
6. Scripps Research scientists find dual switch regulates fat formation
7. Common chaperone protein found to work in surprising way, say Scripps Research scientists
8. Dr. Daniel Von Hoff presented with top genomics award from Scripps
9. Scripps Research team discovers new details about medically important protein family
10. Scripps Research scientists develop new test for pluripotent stem cells
11. Scripps Research scientists create cell assembly line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), a ... “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will lead ... Floyd’s career has spanned 30 years in the chemicals and equipment industries. Sig ...
(Date:3/22/2017)... , March 22, 2017 Good Start ... it has eclipsed the 130 million covered lives mark ... Shield of Texas . With newly ... Company continues to enjoy strong payor acceptance based on ... clinical programs and genetic counseling, its industry-leading customer care ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical ... desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is ... antibodies. , To meet this demand, the team at SCIEX has developed ...
Breaking Biology Technology: